Evidence map›Paper›PMID 39528599›Full record

ArticleInternational journal of obesity (2005)2025

Weight loss and metabolic effects of an ALDH1A1-specific inhibitor, FSI-TN42, in a diet induced mouse model of obesity.

Jisun Paik, Andy Kim, Kevin Fogassy, Jessica M Snyder, Thea Brabb, Kimberly A Dill-McFarland, Qianchuan He, John K Amory

Abstract read
In one paragraph

Article in International journal of obesity (2005), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jisun PaikDepartment of Comparative Medicine, University of Washington, Seattle, WA, USA. jpaik@uw.edu.ORCID 0000-0001-5628-7723
Andy KimDepartment of Comparative Medicine, University of Washington, Seattle, WA, USA.ORCID 0009-0007-1566-9283
Kevin FogassyDepartment of Comparative Medicine, University of Washington, Seattle, WA, USA.
Jessica M SnyderDepartment of Comparative Medicine, University of Washington, Seattle, WA, USA.
Thea BrabbDepartment of Comparative Medicine, University of Washington, Seattle, WA, USA.ORCID 0000-0001-5849-1971
Kimberly A Dill-McFarlandDepartment of Medicine, University of Washington, Seattle, WA, USA.
Qianchuan HePublic Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
John K AmoryDepartment of Medicine, University of Washington, Seattle, WA, USA.

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric Collisson · 1985 to 2026
$296.4M
Vector and Transgenic Mouse CoreP30DK017047 · NIDDK · UNIVERSITY OF WASHINGTON · PI Sakeneh Zraika · 1986 to 2026
$41.4M
PILOT STUDY--CLINICAL NUTRITION RESEARCHP30DK035816 · NIDDK · UNIVERSITY OF WASHINGTON · PI GREGORY J MORTON · 1986 to 2026
$30.4M
Validation of ALDH1A1 as a target for the treatment of obesity: effects of ALDH1A1 inhibition on energy metabolismR01DK124197 · NIDDK · UNIVERSITY OF WASHINGTON · PI PAIK, JISUN · 2022 to 2024
$1.2M
Multiplexed UPLC-MS/MS System for Advanced Target MetabolomicsS10OD021562 · OD · UNIVERSITY OF WASHINGTON · PI RAFTERY, DANIEL · 2016 to 2016
$596k
NCI NIH HHS P30 CA015704NIDDK NIH HHS P30 DK017047NIDDK NIH HHS P30 DK035816NIDDK NIH HHS R01 DK124197NIH HHS 1S10OD021562–01NIH HHS S10 OD021562
6 · The paper itself

Abstract

backgroundRetinoic acid (RA) participates in weight regulation and energy metabolism. Mice lacking ALDH1A1, one of the major enzymes responsible for RA biosynthesis, are resistant to diet-induced obesity. Previously, we identified FSI-TN42 (N42) as an ALDH1A1-specific inhibitor and reported its pharmacokinetics and pharmacodynamics as well as its efficacy in weight suppression.

methodsIn the first study, C57BL/6 J male mice were fed a high fat diet for 8 weeks to induce obesity. Mice were then divided into three groups and fed (1) moderate fat diet (MFD), (2) MFD + WIN 18,446 (1 g/kg diet), or (3) MFD + N42 (1 g/kg diet) for 8 weeks. A control group of mice were fed a low-fat diet for the entire period. Mice were weighed weekly and fasting glucose was determined every 4 weeks. Tissues were examined for potential toxicity using histopathology and complete blood counts. In the second study, we examined influences of N42 on energy balance and/or appetite by determining food intake, activity and energy expenditure in mice with obesity treated with MFD or MFD + N42. Lastly, we tested fertility with a mating study.

resultsN42 significantly accelerated weight loss compared to MFD alone in mice with obesity by reducing fat mass without decreasing lean mass. N42 did not alter food intake or activity levels. While mice treated with N42 lost significantly more weight, they maintained a similar level of energy expenditure compared to mice fed MFD only. Mice fed N42 preferentially used fat postprandially, especially under thermoneutral or mild cold challenge. N42 did not affect male fertility.

conclusionsN42 promotes weight loss when used with MFD in mice with diet-induced obesity without causing significant organ toxicity or male infertility. Future studies will determine if N42 can be used to promote further weight loss if combined with current weight loss drugs.

Indexed as

ObesityWeight LossAldehyde Dehydrogenase 1 FamilyAnimalsDiet, High-FatDisease Models, AnimalEnergy MetabolismMaleMiceMice, Inbred C57BLRetinal DehydrogenaseAldehyde Dehydrogenase 1 FamilyALDH1A1 protein, mouseRetinal Dehydrogenase

Identifiers

PMID39528599
PMCPMC12306646

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.